13 Key Performance Data Summary Performance Indicator Measure 2019/20 2020/21 2021/22 More in 21/22 Annual Report (page reference) Economic Contribution Operating revenue US$ million 9,151¶ 10,310¶ 10,562¶ 98 Net profit US$ million 2,103¶ 2,375¶ 2,255¶ Economic value generated US$ million 9,158† 10,314† 10,570† 48 Economic value distributed US$ million 8,832† 9,959† 9,866† New plasma centres Number 40 25 27 16 Sustainable Workforce Our People Total headcount Number 27,009 25,415 30,398† 37 Total Board female Percentage 44 43 44† Total workforce female Percentage 57 57 61† Total people managers female Percentage 44 44 46† Total senior executives female Percentage 30 30 31 Total Recordable Injury Frequency Rate (TRIFR) Per million hours worked for Non-CSL Plasma sites For all sites – 7.2. Methodology for reporting changed in 19/20 – please see page 41 for more. 1.9† 1.4† 41 Per million hours worked for CSL Plasma 11.2† 10.7† Fatalities (including contractors) Number 0 0† 0† 41 Employee engagement Percentage 76.4† 73.7† 77.9† 40 ESG employee engagement NA NA 78.2† 41 Hotline calls (Ethics) Number 136 259 295 61 Social Innovation R&D investment US$ million 922*† 1,001† 1,156 16 Clinical trials in operation Number 34 43 58 34 New product registrations Number 29 28 24 36 Safety and Quality Regulatory audits of manufacturing facilities and plasma collection centres Number 401*† 365† 406† 50 Quality audits of suppliers Number 476*† 481** 678† Safety related recalls of finished product†† Number 2*† 3† 0† Pharmacovigilance audits Number 50 64 69 50 Community Total contribution US$ million 44.6^ 55.2# 50.0 52 Product access support (subset of total community contribution) US$ million 10.6†^ 20.1#† 17.8† 51 Plasma donors willing to donate again Percentage 99† 99† 95^^ 48 Environment Absolutes§ Energy consumption Petajoules 3.79 3.73 3.92 43 Greenhouse gas emissions Metric kilotonnes 344 326 347 Water consumption Gigalitres 4.25 4.44 4.67 Waste Metric kilotonnes 66.75 59.02 55.54 Waste recycling rate Percentage 46 40 38 * Excludes CSL Behring’s operations in Wuhan, China (previously Ruide). † Data for nominated period has received limited assurance by Ernst & Young. ¶ Operating Revenue and Net Profit extracted from the audited financial statements. †† Safety related recalls relate to finished products which must be retrieved due to a known or possible adverse or health related impact on a patient. These include safety related recalls which are classified as a class 1 and 2 recall by the regulator. § See page 43 for more on reporting boundary. # Accounting practices for CSL Seqirus Australia product donations changed in 2020/21 to account for indirect and direct costs (versus direct only for prior years). ^ Data has been restated upwards to include CSL Seqirus contribution to the World Health Organization which was not disclosed in the 2019/20 Annual Report due to a timing discrepancy. ^^ Data for nominated period has received limited assurance by Ernst & Young. Data collectionmethod changed for the reporting period, see section 9, Plasma donors. ** Quality audits of suppliers undertaken by CSL’s Wuhan, China (previously Ruide) are not included in the reported totals. Processes are yet to be integrated. Data has received limited assurance by Ernst & Young. Reporting Boundary Our disclosure covers the businesses and operations over which we exercise direct control and incorporates CSL Limited, CSL Behring (including CSL Plasma), Seqirus, and global research and development (R&D). This includes our eight manufacturing facilities in Australia, China, Europe, the UK and the US as well as R&D, sales and marketing, distribution and administration activities co-located with these facilities. Other R&D activities, sales and marketing, distribution and administrative activities occurring away from our manufacturing facilities are also covered by this report, including the full network of donation centres, laboratories and administration offices operated by CSL Plasma. CSL Limited Annual Report 2021/22 150
RkJQdWJsaXNoZXIy MjE2NDg3